DuPont has completed the sale of its Aramids business, including Kevlar and Nomex products, to Arclin for about $1.8 billion. The deal provides DuPont with roughly $1.2 billion in pre-tax cash, a $300 million note receivable, and a 16% equity stake in Arclin valued at $325 million. This divestiture reflects DuPont's ongoing strategy to focus on its core markets like healthcare and construction. The Aramids business results have been reported as discontinued operations since Q3 2025, and DuPont will now benefit from its investment in Arclin, a materials science company serving diverse industries globally.
DuPont has introduced a comprehensive Direct Lithium Extraction (DLE) portfolio featuring over 20 products, including sorbents, membranes, and ion exchange resins, designed to enhance lithium recovery from various brine compositions. This integrated ...
DuPont will release its financial results for the second quarter of 2026 on August 4 at 6:00 a.m. ET. The company will also hold a live conference call at 8:00 a.m. ET the same day, accessible via webcast and phone. Investors can find the earnings re...
